This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Recommendations for the Treatment of Chloroquine Retinopathy

MARTIN RUBIN, PhD; HOWARD N. BERNSTEIN, MD; NATHAN J. ZVAIFLER, MD

Arch Ophthalmol. 1963;70(4):474-481.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Introduction

Chloroquine (7-chloro-4- (4-diethylamino1-methylbutylamino) quinoline (Fig 1) was originally developed as an antimalarial agent. In recent years it has been found to be beneficial in a variety of diseases, including rheumatoid arthritis, discoid and systemic lupus erythematosus. When used as a malarial suppressive, 500 mg of chloroquine salt are given once a week. In the treatment of diseases other than malaria, chloroquine is administered in a much larger dosage and more frequently, usually 250 to 750 mg daily.¹

The occurrence of a characteristic retinopathy following the long-term daily ad- ministration of chloroquine has now been well documented.² The fact that the retinal lesion usually develops after one or more years of drug ingestion, plus the remarkably large accumulation of chloroquine in body tissues and organs,^3-5 suggests that the retinopathy may be due to high chloroquine levels in the ocular tissues. The present report concerns the finding of . . . [Full Text PDF of this Article]

Author Affiliations
Washington, DC and Bethesda, Md

From the Departments of Biochemistry and Medicine, Georgetown University School of Medicine, and from the Ophthalmology Branch, National Institute of Neurological Diseases and Blindness, National Institutes of Health, US Public Health Service, Department of Health, Education and Welfare, Bethesda 14, Md.

Footnotes
Submitted for publication April 4, 1963.

This study was supported in part by US Public Health Service Grant 2A-5042 and by the Arthritis and Rheumatism Foundation of Metropolitan Washington, DC.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?